Customers may not want to retrain employees on automated devices or view automation as an unnecessary investment, which would hinder growth in blood technologies.The plasma industry historically has been cyclical, and if demand for plasma starts to weaken or fall lower than supply, then the firm's
Centene could improve its competitive position by better leveraging administrative costs.
Tomo's radiation system is one of the most expensive on the market and represents a huge purchase for clinics and hospitals alike. Health-care entities looking to cut spending may focus on other options.The company's primary product has an extremely long sales cycle, which can make for volatile
With approval of Ofirmev, Cadence needs to transition into an effective commercial firm.
The tailwinds of health-care reform could benefit Magellan Health Services.
PSS could have an emerging economic moat, founded on scale and customer relationships.
Lincare must operate effectively in an increasingly harsh regulatory environment.
Brookdale's strategy of financing growth through debt has significantly raised the financial risk of the business. Any operational missteps would increase the company's risk of defaulting on debt payments and limit its ability to raise future debt.Many of Brookdale's target customers have taken a
As a relatively small player, Iridex remains hampered in its ability to sponsor large clinical trials that could demonstrate the efficacy of its lasers and sway ophthalmologist behavior.Iridex has lost a number of personnel who came with the Laserscope acquisition, raising questions about whether
Although EMS is the market leader in both the ambulance transport and outsourced emergency room services arenas, it only claims single-digit market share. Highly fragmented markets of this nature generally encourage fierce, profitability-impairing competition.With roughly a third of revenue coming